BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 29608318)

  • 1. Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.
    Yadav J; Korzekwa K; Nagar S
    Mol Pharm; 2018 May; 15(5):1979-1995. PubMed ID: 29608318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator.
    Xu L; Chen Y; Pan Y; Skiles GL; Shou M
    Drug Metab Dispos; 2009 Dec; 37(12):2330-9. PubMed ID: 19773538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Static and Dynamic Projections of Drug-Drug Interactions Caused by Cytochrome P450 3A Time-Dependent Inhibitors Measured in Human Liver Microsomes and Hepatocytes.
    Tseng E; Eng H; Lin J; Cerny MA; Tess DA; Goosen TC; Obach RS
    Drug Metab Dispos; 2021 Oct; 49(10):947-960. PubMed ID: 34326140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats.
    Zhang X; Galinsky RE; Kimura RE; Quinney SK; Jones DR; Hall SD
    Drug Metab Dispos; 2010 Jan; 38(1):61-72. PubMed ID: 19797607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome P450 3A Time-Dependent Inhibition Assays Are Too Sensitive for Identification of Drugs Causing Clinically Significant Drug-Drug Interactions: A Comparison of Human Liver Microsomes and Hepatocytes and Definition of Boundaries for Inactivation Rate Constants.
    Eng H; Tseng E; Cerny MA; Goosen TC; Obach RS
    Drug Metab Dispos; 2020 Jun; 49(6):442-450. PubMed ID: 33811106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems.
    Albaugh DR; Fullenwider CL; Fisher MB; Hutzler JM
    Drug Metab Dispos; 2012 Jul; 40(7):1336-44. PubMed ID: 22490230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Time Dependent Inhibition Assays for Marketed Oncology Drugs: Comparison of Human Hepatocytes and Liver Microsomes in the Presence and Absence of Human Plasma.
    Mao J; Tay S; Khojasteh CS; Chen Y; Hop CE; Kenny JR
    Pharm Res; 2016 May; 33(5):1204-19. PubMed ID: 26869174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive evaluation of liver microsomal cytochrome P450 3A (CYP3A) inhibition: comparison of cynomolgus monkey and human.
    Haarhoff ZE; Kramer MA; Zvyaga TA; Zhang J; Bhutani P; Subramanian M; Rodrigues AD
    Xenobiotica; 2017 Jun; 47(6):470-478. PubMed ID: 27498589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems.
    Lutz JD; VandenBrink BM; Babu KN; Nelson WL; Kunze KL; Isoherranen N
    Drug Metab Dispos; 2013 Dec; 41(12):2056-65. PubMed ID: 23785064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
    Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
    Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interactions.
    Chen Y; Liu L; Monshouwer M; Fretland AJ
    Drug Metab Dispos; 2011 Nov; 39(11):2085-92. PubMed ID: 21835977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.
    Yadav J; Paragas E; Korzekwa K; Nagar S
    Pharmacol Ther; 2020 Feb; 206():107449. PubMed ID: 31836452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug Interactions.
    Zetterberg C; Maltais F; Laitinen L; Liao S; Tsao H; Chakilam A; Hariparsad N
    Drug Metab Dispos; 2016 Aug; 44(8):1286-95. PubMed ID: 27298338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition.
    Zhang X; Jones DR; Hall SD
    Drug Metab Dispos; 2009 Jan; 37(1):150-60. PubMed ID: 18854379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
    Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
    Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Assessment Using Cytochrome P450 Time-Dependent Inhibition Assays at Single Time and Concentration in the Early Stage of Drug Discovery.
    Kosaka M; Kosugi Y; Hirabayashi H
    J Pharm Sci; 2017 Sep; 106(9):2839-2846. PubMed ID: 28483425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process.
    Watanabe A; Nakamura K; Okudaira N; Okazaki O; Sudo K
    Drug Metab Dispos; 2007 Jul; 35(7):1232-8. PubMed ID: 17392390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
    Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
    Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
    Fenneteau F; Poulin P; Nekka F
    J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Strategies for the Assessment of Drug-Drug Interactions Involving Cytochrome P450 Enzymes.
    Reinen J; Smit M; Wenker M
    Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):737-750. PubMed ID: 29785610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.